AA
VKTX icon

ALPS Advisors’s Viking Therapeutics VKTX Stock Holding History

ALPS Advisors’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-94,070
Closed -$3.06M – 1217
2026
Q1 		$3.06M Buy
94,070
+1,454
+2% +$46.7K 0.01% 329
2025
Q4 		$3.26M Buy
92,616
+37,782
+69% +$1.34M 0.02% 315
2025
Q3 		$1.44M Sell
54,834
-5,795
-10% -$173K 0.01% 441
2025
Q2 		$1.61M Buy
+60,629
New +$1.6M 0.01% 398
2024
Q2 		– Sell
-74,007
Closed -$6.07M – 1006
2024
Q1 		$6.07M Buy
74,007
+7,630
+11% +$340K 0.04% 213
2023
Q4 		$1.24M Sell
66,377
-7,428
-10% -$97.1K 0.01% 418
2023
Q3 		$817K Buy
73,805
+418
+0.6% +$5.98K 0.01% 513
2023
Q2 		$1.19M Buy
73,387
+21,669
+42% +$454K 0.01% 432
2023
Q1 		$861K Sell
51,718
-325
-0.6% -$3.36K 0.01% 501
2022
Q4 		$489K Buy
+52,043
New +$232K ﹤0.01% 596
2022
Q2 		– Sell
-80,540
Closed -$242K – 1093
2022
Q1 		$242K Sell
80,540
-9,999
-11% -$35.9K ﹤0.01% 792
2021
Q4 		$416K Sell
90,539
-5,296
-6% -$29.7K ﹤0.01% 620
2021
Q3 		$602K Sell
95,835
-7,030
-7% -$43.4K 0.01% 479
2021
Q2 		$616K Sell
102,865
-29,113
-22% -$173K 0.01% 493
2021
Q1 		$835K Buy
131,978
+469
+0.4% +$3.3K 0.01% 420
2020
Q4 		$740K Buy
131,509
+38,719
+42% +$235K 0.01% 423
2020
Q3 		$540K Sell
92,790
-6,237
-6% -$42.9K 0.01% 415
2020
Q2 		$714K Sell
99,027
-32,351
-25% -$215K 0.01% 385
2020
Q1 		$615K Sell
131,378
-15,322
-10% -$94.2K 0.01% 409
2019
Q4 		$1.18M Buy
146,700
+2,681
+2% +$19.5K 0.01% 307
2019
Q3 		$991K Sell
144,019
-6,791
-5% -$50.4K 0.01% 314
2019
Q2 		$1.25M Sell
150,810
-21,793
-13% -$186K 0.01% 285
2019
Q1 		$1.72M Buy
172,603
+7,458
+5% +$62.4K 0.01% 245
2018
Q4 		$1.26M Buy
+165,145
New +$1.97M 0.01% 256

Other funds holding VKTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

ALPS Advisors's VKTX Position: Q2 2026 in Review

ALPS Advisors sold out of Viking Therapeutics (VKTX) in Q2 2026, closing a stake of 94,070 shares — an estimated $3.06M sold.

ALPS Advisors first reported a position in VKTX in Q4 2018 and held it in 24 quarters. The position peaked at $6.07M in Q1 2024. 436 funds tracked by Wall St. Rank hold VKTX as of Q2 2026.

  • ALPS Advisors reported no remaining Viking Therapeutics position as of Q2 2026 after selling out during the quarter.
  • ALPS Advisors sold 94,070 Viking Therapeutics shares in Q2 2026, an estimated $3.06M.
  • ALPS Advisors first reported a position in Viking Therapeutics in Q4 2018 and held it in 24 quarters.
  • ALPS Advisors's Viking Therapeutics position peaked at $6.07M in Q1 2024.
  • 436 funds tracked by Wall St. Rank held Viking Therapeutics as of Q2 2026.

Based on ALPS Advisors's 13F filing for Q2 2026, filed 29 Jul 2026.